LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients
Paul Russell (London, United Kingdom), Paul Russell, Chris Stevenson, Catherine Charron, Charlie Brindley, Dave Singh
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Session: Emerging strategies for airway disease treatments
Session type: Thematic Poster Session
Number: 4361
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Paul Russell (London, United Kingdom), Paul Russell, Chris Stevenson, Catherine Charron, Charlie Brindley, Dave Singh. LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients. Eur Respir J 2015; 46: Suppl. 59, 4361
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
LATE-BREAKING ABSTRACT: Single-dose safety, tolerability, PD & PK of AZD8999, a bi-functional muscarinic antagonist/β2-agonist (MABA), in patients with COPD Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
LATE-BREAKING ABSTRACT: Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPD Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016
Population pharmacokinetics and pharmacodynamics of GSK961081 (MABA) in patients with moderate to severe COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
The effect of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, on potential biomarkers measured from the lungs of healthy male smokers Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Safety, tolerability and pharmacokinetics (PK) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, administered to healthy male subjects in a phase I study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
LATE-BREAKING ABSTRACT: A useful physiological marker for evaluating the effect of indacaterol in COPD patients. Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013
LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist Source: International Congress 2016 – Asthma management Year: 2016
Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Clinical, functional and laboratory assessment of treatment efficacy in COPD patients Source: International Congress 2014 – Predictors Year: 2014